Could vimseltinib be the next big thing in TGCT treatment? FDA says Yes!
The U.S. Food and Drug Administration (FDA) has granted priority review status to Deciphera Pharmaceuticals, Inc.’s New Drug Application (NDA) for vimseltinib, a drug developed to treat tenosynovial giant cell tumor (TGCT). The FDA’s target action date for this review is February 17, 2025. This development follows the European Medicines Agency’s (EMA) acceptance of Deciphera’s […]